Amunix’s Omega-led $73M A round to support shift to drug development

The potential for Amunix’s protein polymer technology to overcome toxicity issues that have plagued two growing immuno-oncology modalities convinced Omega Funds to lead the biotech’s $73 million series A. The round, together with cash from a January licensing deal with Roche, will fund Amunix’s pivot to drug development, enabling it to apply its XTEN platform towards an in-house pipeline of T cell engager and cytokine therapeutics.

Existing investor Frazier Healthcare also participated in Amunix Pharmaceuticals Inc.’s untranched round, as did new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock and Delian Capital...